Covid-19ワクチンとマイナス70度の壁

mRNAワクチンに関しては色々情報があるようだが

https://news.yahoo.co.jp/byline/katasekei/20200224-00164375/

ワクチン接種が現実味を帯びるとリアルな問題点が浮上

News

Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate

BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4347 (Published 09 November 2020)

Cite this as: BMJ 2020;371:m4347

https://www.bmj.com/content/371/bmj.m4347.short

A vaccine candidate developed by Pfizer and BioNTech may be more than 90% effective in preventing covid-19 in participants without prior infection, the first interim analysis of the phase III trial shows.

The research team evaluated the results after 94 cases of covid-19 had been confirmed. The study began in July and has so far enrolled nearly 44 000 participants, just under 39 000 of whom have received a second dose of the mRNA vaccine candidate (as of 8 November).

The team’s announcement said, “The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a two-dose schedule.” However, the results, which are the first from any phase III trial of a covid-19 vaccine, have been shared only by press release and have not yet been published or peer reviewed.

The clinical trial will continue through to final analysis at 164 confirmed cases, so as to collect further data and assess other endpoints such as efficacy based on cases occurring 14 days after the second dose.

最後の一文が非常に気になる！

He said that logistical problems with the vaccine would need to be tackled, as it has been reported that it requires storage at −70°C. “That is not necessarily routinely available in most health centres even in the UK, let alone globally.”

すでに新聞記事になっていた

ワクチン大量接種を阻むマイナス70度の壁　「残っていない」集団接種のノウハウ

https://mainichi.jp/articles/20201102/k00/00m/040/274000c